» Articles » PMID: 33369107

Predictive Value of Protease-activated Receptor-2 (PAR ) in Cervical Cancer Metastasis

Overview
Journal J Cell Mol Med
Date 2020 Dec 28
PMID 33369107
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Metastasis is the primary cause of an unfavourable prognosis in patients with malignant cancer. Over the last decade, the role of proteinases in the tumour microenvironment has attracted increasing attention. As a sensor of proteinases, proteinase-activated receptor 2 (PAR ) plays crucial roles in the metastatic progression of cervical cancer. In the present study, the expression of PAR in multiple types of cancer was analysed by Gene Expression Profiling Interactive Analysis (GEPIA). Kaplan-Meier plotter was used to calculate the correlation between survival and the levels of PAR , Grb-associated binding protein 2(Gab2) and miR-125b. Immunohistochemistry (IHC) was performed to examine PAR expression in a tissue microarray (TMA) of CESCs. Empower Stats was used to assess the predictive value of PAR in the metastatic potential of CESC. We found that PAR up-regulation was observed in multiple types of cancer. Moreover, PAR expression was positively correlated with the clinicopathologic characteristics of CESC. miR-125b and its target Gab2, which are strongly associated with PAR -induced cell migration, are well-characterized as predictors of the prognostic value of CESC. Most importantly, the Cancer Genome Atlas (TCGA) data set analysis showed that the area under the curve (AUC) of the PAR model was significantly greater than that of the traditional model (0.833 vs 0.790, P < .05), demonstrating the predictive value of PAR in CESC metastasis. Our results suggest that PAR may serve as a prognostic factor for metastasis in CESC patients.

Citing Articles

Non-linear association between AKI alert detection rate by physicians and medical costs.

Ai H, Jiang E, Wang H, Yang Q, Jin Q, Wan L PLoS One. 2025; 20(2):e0314907.

PMID: 40009619 PMC: 11864515. DOI: 10.1371/journal.pone.0314907.


Bioinformatics and experimental insights into F2RL1 as a key biomarker in cervical cancer diagnosis and prognosis.

Dai Y, Li C, Cheng S, Wang H, Zhuang X Sci Rep. 2025; 15(1):5228.

PMID: 39939734 PMC: 11821865. DOI: 10.1038/s41598-025-89746-y.


Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy.

Huo H, Feng Y, Tang Q Cancer Chemother Pharmacol. 2024; 93(5):397-410.

PMID: 38172304 PMC: 11043148. DOI: 10.1007/s00280-023-04630-8.


The role of cellular proteostasis in antitumor immunity.

Mercier R, LaPointe P J Biol Chem. 2022; 298(5):101930.

PMID: 35421375 PMC: 9108985. DOI: 10.1016/j.jbc.2022.101930.


TMEM45A Affects Proliferation, Apoptosis, Epithelial-Mesenchymal Transition, Migration, Invasion and Cisplatin Resistance of HPV-Positive Cervical Cancer Cell Lines.

Liu Y, Liu L, Mou Z Biochem Genet. 2021; 60(1):173-190.

PMID: 34143331 DOI: 10.1007/s10528-021-10094-3.


References
1.
Xiao Y, Humphries B, Yang C, Wang Z . MiR-205 Dysregulations in Breast Cancer: The Complexity and Opportunities. Noncoding RNA. 2019; 5(4). PMC: 6958506. DOI: 10.3390/ncrna5040053. View

2.
de Albuquerque A, Kubisch I, Stolzel U, Ernst D, Boese-Landgraf J, Breier G . Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients. J Transl Med. 2012; 10:222. PMC: 3508882. DOI: 10.1186/1479-5876-10-222. View

3.
Hugo de Almeida V, Santos Guimaraes I, Almendra L, Rondon A, Tilli T, de Melo A . Positive crosstalk between EGFR and the TF-PAR2 pathway mediates resistance to cisplatin and poor survival in cervical cancer. Oncotarget. 2018; 9(55):30594-30609. PMC: 6078136. DOI: 10.18632/oncotarget.25748. View

4.
Wang X, Zhang Z, Pan L, Cao X, Xiao C . KRT19 and CEACAM5 mRNA-marked circulated tumor cells indicate unfavorable prognosis of breast cancer patients. Breast Cancer Res Treat. 2018; 174(2):375-385. DOI: 10.1007/s10549-018-05069-9. View

5.
Ma L . MicroRNA and Metastasis. Adv Cancer Res. 2016; 132:165-207. DOI: 10.1016/bs.acr.2016.07.004. View